Dec 17 (Reuters) - Chemicals maker Johnson Matthey will sell its health business to investment firm Altaris Capital Partners for an enterprise value of about 325 million pounds ($433 million), about eight months after it began a review of the division.

The London-listed company said on Friday it would retain a 30% stake in the business, which develops and manufactures specialist and complex active pharmaceutical ingredients for pharma and biotech customers. ($1 = 0.7508 pounds) (Reporting by Muhammed Husain in Bengaluru; Editing by Sriraj Kalluvila)